Patents Assigned to 149 Bio, LLC
  • CD11B AGONISTS FOR TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20260137662
    Abstract: Described herein are novel methods for the prevention and/or treatment of autoimmune diseases after disease onset associated with CD11b/CD18 activity, such as systemic lupus erythematosus (SLE), comprising administering a therapeutically effective amount of CD11b agonist LA1 ((Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid) or it's choline salt.
    Type: Application
    Filed: October 16, 2023
    Publication date: May 21, 2026
    Applicants: Rush University Medical Center, 149 Bio, LLC
    Inventors: Vineet GUPTA, Xiabo LI, Veronica VILLANUEVA, Billy NGUYEN, Antonio BARBOSA
  • Reagents and assays using modified integrin domains
    Patent number: 12291562
    Abstract: Modified integrin polypeptides are provided. Methods of identifying binding agents that bind to a modified integrin polypeptide are also provided.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: May 6, 2025
    Assignees: Rush University Medical Center, 149 Bio, LLC
    Inventors: Vineet Gupta, Antonio J. Barbosa
  • Reagents and Assays using Modified Integrin Domains
    Publication number: 20220204585
    Abstract: Modified integrin polypeptides are provided. Methods of identifying binding agents that bind to a modified integrin polypeptide are also provided.
    Type: Application
    Filed: March 31, 2020
    Publication date: June 30, 2022
    Applicants: Rush University Medical Center, 149 Bio, LLC
    Inventors: Vineet GUPTA, Antonio J. BARBOSA